Introduction {#s1}
============

In late December 2019, an outbreak of pneumonia caused by a novel human coronavirus SARS-CoV-2 (also referred to 2019-nCov) emerged in Wuhan, Hubei province in China \[[@C1], [@C2]\]. The novel emerging virus has rapidly spread across China, and to more than 200 countries/regions outside of China (World Health Organisation, COVID-19 Situation Report-129) \[[@C3]\]. Data as of 28 May 2020, SARS-CoV-2 has affected more than 5 593 631 patients (353 334 deaths) worldwide (WHO, COVID-19 Situation Report-129). Due to its rapid spreading speed (R~0~ 3.28), possible fatal progression and strong infectivity, COVID-19 has stirred a grave global concern \[[@C4]\]. Hence, a rapid, easy-to-use and reliable test tool was urgently required for diagnosing infections, treating the patients and controlling the spreading of COVID-19.

Early diagnosis of COVID-19 is extremely difficult only according to manifestations, which are highly variable \[[@C5]\]. The clinical manifestations of COVID-19 patients range from asymptomatic infection, non-specific flu-like clinical presentations (such as cough and fever) to respiratory failure \[[@C3]\]. Obvious clinical manifestations may occur in 2 days, even up to 2 weeks after exposure. Thus, designing a rapid and early diagnostic method, is vital for treatment and disease control. Currently, the definitive diagnosis of COVID-19 infections strongly relies on polymerase chain reaction (PCR)-based methods, such as reverse transcription PCR (RT-PCR) and real-time reverse transcription PCR (rRT-PCR) \[[@C5]\]. However, they require an expensive thermal cycle apparatus and very skillful laboratory workers. In addition, only 62% positive rate obtained by PCR-based technologies because of their sensitivity limitation among clinical diagnosed COVID-19 patients is not effective for control of infection \[[@C5], [@C6]\]. Thus, an easy-to-use and cost-effective test with higher sensitivity is needed as a first-line technique to tackle the COVID-19 in field and clinical settings.

Recently, several loop-mediated isothermal amplification (LAMP) assays have been devised for rapid detection of COVID-19 in clinical and stimulated patient samples \[[@C7]--[@C9]\]. However, the developed COVID-19 LAMP assays only detect one target gene (Open reading frame 1a/b; F1ab). False-positive results could be produced when they were applied to detect clinical samples containing highly homologous sequences, such as gene from bat severe acute respiratory syndrome-like coronavirus (GenBank KY417152.1). In addition, LAMP results were reported *via* agarose gel electrophoresis, SYBR dyes or PH indicator. Particularly, the electrophoresis is a tedious and time-consuming process, and the assessment of color change with the unaided eye is potentially subjective in an ambiguous test caused by the low concentration of templates. Herein, novel techniques, which could overcome these technical difficulties, are continuously demanded.

Multiple cross displacement amplification (MCDA) technique is an easy-to-perform and reliable diagnostic assay, which amplifies the target nucleic acid under conditions (usually between 58°C and 69°C) within a short time (20 min--40 min, usually 30 min) \[[@C10]\]. Only a simple equipment (such as a water bath, a heating block, even a thermo cup) is sufficient for MCDA test. The MCDA technique has been used for diagnosing various infectious diseases producing positive results from down to 3 copies of target sequence, which has shown its rapidity, simplicity, high specificity characteristics \[[@C11], [@C12]\]. To achieve a simultaneous detection of multiple targets and rapid analysis of MCDA products, nanoparticles-based biosensor has been coupled with MCDA to achieve an objective detection results. Biosensor is simple, easy-to-conduct and low-cost, and does not need complex instrument and skilled personnel \[[@C13]\].

In this report, we devised a one-step, single-tube reverse transcription MCDA (RT-MCDA) coupled with nanoparticles-based biosensor (BS) assay (RT-MCDA-BS) ([figs. 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}), which could diagnose COVID-19 by simultaneously detecting F1ab (open reading frame 1a/b) and N (nucleoprotein) genes. The whole detection process could be completed within 1 h with high accuracy. Thus, the RT-MCDA-BS method may enable the diagnosis of COVID-19 easier, faster and more reliable, even in resource-limited settings.

![Mechanistic description of the COVID-19 RT-MCDA-BS assay. a) Preparing the COVID-19 RT-MCDA reaction mixtures. b) One-step, single-tube reverse transcription MCDA reaction. c) The detectable COVID-19 RT-MCDA products were formed.](ERJ-02060-2020.01){#F1}

![Schematic illustration of the principle of BS for visualisation of COVID-19 RT-MCDA products. a) The details of BS. b) The test principle and steps of BS for COVID-19 RT-MCDA amplicons. c) Interpretation of the detection results. I, negative (only the control line appears on the BS); II, a positive result for F1ab (TL1 and CL appear on the detection region); III, a positive result for N (TL2 and CL appear on the detection region); IV, a positive result for F1ab and N (TL1, TL2 and CL appear on the BS).](ERJ-02060-2020.02){#F2}

Methods {#s2}
=======

Preparation of nanoparticles-based biosensor {#s2a}
--------------------------------------------

The nanoparticles-based biosensor (BS, 4 mm×60 mm), depicted in [figure 2a](#F2){ref-type="fig"}, consisted of a sample pad, a conjugate pad, a nitrocellulose membrane (NC membrane) with an absorbent pad assembled on a plastic adhesive backing card (Jie-Yi Biotechnology. Co., Ltd. Shanghai, China). The capture reagents, including anti-Dig (sheep anti-digoxigenin antibody, 0.25 mg·mL^−1^, Abcam. Co., Ltd.), anti-FITC (rabbit anti-fluorescein antibody, 0.2 mg·mL^−1^, Abcam. Co., Ltd.) and biotin-BSA (biotinylated bovine serum albumin, 4 mg·mL^−1^, Abcam. Co., Ltd.), were dispensed onto the NC membrane as the test line 1 (TL1), test line 2 (TL2) and control line (CL), respectively, with each line separated by 5 mm. The detector reagents (Dye streptavidin coated polymer nanoparticles, 129 nm, 10 mg·mL^−1^, 100 mM borate, pH 8.5 with 0.1% BSA, 0.05% Tween 20 and 10 mM EDTA) were sprayed onto the conjugate region of the biosensor. Thus, the biosensor can detect three targets, including two target products (F1ab MCDA amplicons and N MCDA amplicons) and a chromatography control. Finally, the assembled biosensors were cut into 4-mm dipsticks, and dryly stored at the room temperature for use.

RT-MCDA Primer design {#s2b}
---------------------

Two sets of RT-MCDA primers (F1ab-MCDA and N-MCDA primer sets), which targeted F1ab gene and N gene of COVID-19 (GenBank MN908947, Wuhan-Hu-1), were designed according the MCDA principle ([fig. 3](#F3){ref-type="fig"}). Each MCDA primer set consists of two displacement primers (F1 and F2), two cross primers (CP1 and CP2), and six amplification primers (C1, D1, R1, C2, D2 and R2). The specificity of F1ab- and N-MCDA primer sets were analysed by National Center for Biotechnology Information BLAST. Moreover, the OligoAnalyzer online software (V3.1, Integrated DNA Technologies, Coralville, IA) was employed for primer dimer and secondary structure investigation. The details of RT-MCDA primer design, primer location, sequences and modifications were listed in [figure 3](#F3){ref-type="fig"} and [Table S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials). All oligomers were synthesised and purified by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China) at HPLC purification grade.

![Primer design of COVID-19 RT-MCDA-BS assay. **Up row**, COVID-19 genome organisation (GenBank: MN908947, Wuhan-Hu-1), and the length of all genes is not drawn in scale. F1ab (Open reading frame 1a/b); S (Spike protein); E (Envelope protein); M (Membrane protein); N (Nucleoprotein); Accessory proteins (3, 6, 7a, 7b, and 9b). **Bottom row**, nucleotide sequence and location of F1ab and N gene used to design COVID-19 RT-MCDA primers. Part of nucleotide sequences of F1ab (**Left**) and N (**Right**) are shown. The sites of primer sequence were underline. Right arrows and Left arrows showed the sense and complementary sequence that are used.](ERJ-02060-2020.03){#F3}

Reverse transcription MCDA (RT-MCDA) reaction {#s2c}
---------------------------------------------

The standard RT-MCDA (F1ab-MCDA/N-MCDA) was conducted in a one-step reaction in a 25-μL mixture containing 12.5 μL 2×isothermal reaction buffer \[40 mM Tris-HCl (pH 8.8), 40 mM KCl, 16 mM MgSO~4~, 20 mM (NH4)~2~SO~4~, 2 M betaine and 0.2% Tween-20\], 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 10 U of the avian myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP, 1.4 mM dGTP, 1.4 mM dTTP, 0.1 mM biotin-14-dCTP, 0.1 mM biotin-14-dATP, 0.4 μM each of displacement primers F1 and F2, 0.8 μM each of amplification primers C1, C2, D1, D1, R1 and R2, 0.8 μM each of cross primers CP1\* and CP1, 1.6 μM cross primers CP2 and template (1 μL for the standard plasmid).

The COVID-19 RT-MCDA was also performed in a one-step reaction in a 25-μL mixture containing 12.5 μL 2×isothermal reaction buffer \[40 mM Tris-HCl (pH 8.8), 40 mM KCl, 16 mM MgSO~4~, 20 mM (NH4)~2~SO~4~, 2 M betaine and 0.2% Tween-20\], 8 U of Bst 2.0 DNA polymerase (New England Biolabs), 10 U of the avian myeloblastosis virus reverse transcriptase (Invitrogen), 1.4 mM dATP, 1.4 mM dCTP, 1.4 mM dGTP, 1.4 mM dTTP, 0.1 mM biotin-14-dCTP, 0.1 mM biotin-14-dATP, 0.275 μM of F1ab-F1 and F1ab-F2, 0.55 μM of F1ab-C1, F1ab-C2, F1ab-D1, F1ab-D2, F1ab-R1 and F1ab-R2, 0.55 μM of F1ab-CP1\* and CP1, 1.1 μM of F1ab-CP2, 0.125 μM of N-F1 and N-F2, 0.25 μM of N-C1, N-C2, N-D1, N-D2, N-R1 and N-R2, 0.25 μM of N-CP1\* and CP1, 0.5 μM of N-CP2, and template (1 μL for the each standard plasmid, 5 μL for samples).

Real-time turbidity (LA-320C), visual detection reagents (VDR) and BS were applied to demonstrating the MCDA reactions and confirming the optimal amplification temperature.

Sensitivity of the RT-MCDA-BS assay {#s2d}
-----------------------------------

Two plasmids (F1ab-plasmid and N-plasmid), which contain the F1ab and N genes, respectively, were commercially constructed by Tianyi-Huiyuan Biotech. Co., Ltd. (Beijing, China). According to manual, the initial concentrations of F1ab- and N-plasmids were 5×10^8^ copies·µL^−1^. Then, ten-fold serial dilutions (5×10^4^ to 5×10^−2^ copies) of F1ab-plasmid and N-plasmid were used to assess the limit of detection (LoD) of the COVID-19 RT-MCDA, F1ab-RT-MCDA and N-RT-MCDA assays. The examinations were conducted in triplicate independently. Simultaneously, the concentration of plasmid at the LoD level was used for confirming the optimal isothermal time of COVID-19 RT-MCDA assay.

Specificity of the COVID-19 RT-MCDA-BS assay {#s2e}
--------------------------------------------

The analytical specificity of the COVID-19 RT-MCDA-BS assay was evaluated by comparing COVID-19 templates with the templates extracted from various viruses, bacteria and fungi ([Table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)).

Validating the feasibility of COVID-19 RT-MCDA-BS using clinical samples {#s2f}
------------------------------------------------------------------------

A total of 54 clinical samples (including face, anal, nasal, pharyngeal swabs) were obtained from acute phase and convalescent of COVID-19 sent to the Guizhou province CDC ([Table S3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). Analysis of these RNA templates using COVID-19 RT-MCDA-BS assay was approved by Guizhou province CDC. The pharyngeal, nasal and anal swabs samples were collected using a Flocked sterile plastic swab applicator, which was placed in a Universal Viral Transport Medium (UVIM) for viruses (HiDNA biotech. Co., Ltd.). For faecal sample, aliquots (approximately 1 g) of the stools were placed into a tube, which contained 1.5 ML of UVIM. Then, the faecal sample was centrifuged at 5000 g for 10 min, and the supernatant was placed into a new tube. Particularly, aliquots (200 µL) of UVIM (pharyngeal, nasal and anal swabs samples) and supernatant of faecal samples were subjected to extract the RNA templates, and the procedure only required 15 min using a rapid RNA Extraction Kit (TianLong Biotech. Co., LtD.). Aliquots of 5 µL of templates were used for conducting the RT-PCR and COVID-19 RT-MCDA-BS methods. The RNA templates extracted from different types of clinical samples were collected after rRT-PCR performance in Guizhou province CDC, which was conducted by officially approved clinical RT-PCR kit. The LoD (limit of detection) of RT-PCR diagnosis kit was 500 copies·mL^−1^ according its manual. A Ct value is \<37, which is defined as a positive result for COVID-19 infection. A Ct value is \>40, or no Ct value is obtained, which is defined as a negative result for COVID-19 infection. A Ct value between 37--40 is indeterminate, and the test should be examined again. In addition, 118 pharyngeal swabs samples collected from non-COVID-19 patients also were tested for validating the specificity of the COVID-19 RT-MCDA-BS method.

Results {#s3}
=======

The schematic mechanism of COVID-19 RT-MCDA-BS assay {#s3a}
----------------------------------------------------

In the COVID-19 RT-MCDA system, two core primers, including F1ab-CP1 and N-CP1 primer, are labelled at the 5\' end with digoxigenin (Dig) and fluorescein (FITC), respectively. The new F1ab-CP1 and N-CP1 primers were termed as F1ab-CP1\* and N-CP1\*. Simultaneously, two components (biotin-14-dCTP and biotin-14-dATP) are added into the COVID-19 RT-MCDA reaction mixtures ([fig. 1a](#F1){ref-type="fig"}). As shown in [figure 1b](#F1){ref-type="fig"}, the SARS-CoV-2 templates (RNA) are firstly converted to cDNA with the supplement of avian myeloblastosis virus reverse transcriptase (AMV) at the amplification temperature (64°C). Then, the cDNA serves as the template for MCDA amplification. The F1ab-CP1\* and N-CP1\* primers anneal to the target regions, and is extended by the displacement enzyme (*Bst* 2.0), thus biotin-14-dATP and biotin-14-dCTP are incorporated into the newly synthesised products. As a result, a plenty of detectable double-labelled products are formed with F1ab-MCDA amplicons simultaneously labelled with Dig and biotin, and N-MCDA amplicons for FITC and biotin ([fig. 1c](#F1){ref-type="fig"}).

The principle of BS visualisation of COVID-19 RT-MCDA results {#s3b}
-------------------------------------------------------------

The details of nanoparticles-based biosensor (BS) were shown in [figure 2a](#F2){ref-type="fig"}. After amplification, aliquots (1 μL) of COVID-19 RT-MCDA products were deposited on the sample pad of BS ([fig. 2b](#F2){ref-type="fig"}, step 1), followed by the addition of an aliquot (100 μL) of running buffer to the same region ([fig. 2b](#F2){ref-type="fig"}, step 2). The running buffer can move along BS through capillary action, and then rehydrate the immobilised SA-DNPs in conjugate region. F1ab-MCDA amplicons were specifically captured by the anti-Dig fixed on the TL1, and the N-MCDA amplicons captured by the anti-FITC immobilised in the TL2. The biotins of COVID-19 MCDA products can bind SA-DNPS for visualisation. The excess SA-DNPs were captured by biotinylated bovine serum albumin immobilised in CL, which evaluated the working condition of BS ([fig. 2b](#F2){ref-type="fig"}, step 3). The interpretation of the COVID-19 RT-MCDA results *via* BS was displayed in [figure 2c](#F2){ref-type="fig"}.

Confirmation and analysis of F1ab-, N- and COVID-19 RT-MCDA products {#s3c}
--------------------------------------------------------------------

Using VDR, the positive F1ab-, N- and COVID-19 RT-MCDA vessels were visualised by unaided eye as light green, while the vessels of negative and blank controls remained colorlessness ([Figure S1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials), top row). In BS, two red bands (TL1 and CL) were seen in positive F1ab-RT-MCDA amplification ([Figure S1A](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials), bottom row), TL2 and CL for positive N-RT-MCDA amplification ([Figure S1B](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials), bottom row). TL1, TL2 and CL simultaneously appeared in the detection region of BS indicate positive result of COVID-19 RT-MCDA amplification ([Figure S1C](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials), bottom row). Only the CL shown represents negative and blank controls ([Figure S1A, S1B, S1C](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials), bottom row). These data demonstrated that F1ab- and N-MCDA primer sets, and COVID-19 RT-MCDA assay were feasible for target sequence detection. Then, the optimal reaction temperature of 64°C of COVID-19 RT-MCDA was also determined ([Figure S2 and S3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)).

Sensitivity of COVID-19 RT-MCDA-BS assay {#s3d}
----------------------------------------

As shown in [figure 4](#F4){ref-type="fig"}, the COVID-19 RT-MCDA-BS assay can detect down to 5 copies of either F1ab-plasmid or N-plasmid in a vessel. Of note, F1ab and N gene of COVID-19 were simultaneously amplified correctly with their own primers in a one-step, single-tube reaction ([fig. 4a](#F4){ref-type="fig"}). The results obtained *via* BS were consistent with VDR reagent and real-time turbidity, while the VDR and real-time turbidity methods could not achieve multiple target detection ([figs. 4b](#F4){ref-type="fig"} and c). Most importantly, F1ab- and N-RT-MCDA assays also revealed a detection limit of 5 copies of target sequences in a reaction, which was in consistent with COVID-19 RT-MCDA assay ([Figure S4, S5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials) and [fig. 4](#F4){ref-type="fig"}).

![Sensitivity of COVID-19 RT-MCDA-BS assay using serially diluted plasmid templates. a) BS applied for reporting the results; (b) Real-time turbidity applied for reporting the results; (c) VDR applied for reporting the results. BS (a)/Signals (b)/Tubes (c) 1--8 represented the plasmid levels (each of F1ab- and N-plasmids) of 5×10^4^, 5×10^3^, 5×10^2^, 5×10^1^, 5×10^0^, 5×10^−1^, 5×10^−2^ copies per reaction and blank control (DW). The plasmid levels of 5×10^4^ to 5×10^0^ copies per reaction produced the positive reactions.](ERJ-02060-2020.04){#F4}

The optimal reaction time required for the COVID-19 RT-MCDA-BS assay during the amplification stage was also tested. The lowest template level (5×10^0^ copies of either F1ab- or N-plasmids displayed three red bands (TL1, TL2 and CL) when the isothermal reaction was conducted for 25 min at 64°C ([Figure S6](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). For the clinical sample analysis, therefore, a reaction time of 35 min was recommended including the reverse transcription process (10 min). Thus, the whole diagnosis procedure of COVID-19 RT-MCDA-BS technique, including sample collection (3 min), rapid template preparation (15 min), RT-MCDA reaction (35 min) and result reporting (\<2 min), can be completed within 1 h ([fig. 5](#F5){ref-type="fig"}).

![The workflow of COVID-19 RT-MCDA-BS assay. A total of four steps, including sample collection (3 min), rapid template preparation (15 min), RT-MCDA reaction (35 min) and result reporting (within 2 min), were required for the COVID-19 RT-MCDA-BS assay, and the total procedure could be completed within 60 min.](ERJ-02060-2020.05){#F5}

Specificity of COVID-19 RT-MCDA-BS assay {#s3e}
----------------------------------------

COVID-2019 RT-MCDA-BS assay specifically detected the positive control (containing 5×10^3^ copies of each F1ab- and N-plasmids), while other target templates from non-COVID-19 virus, bacteria and fungi were not detected ([Table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). This suggested that the COVID-2019 RT-MCDA-BS assay has a very good specificity.

Evaluation of COVID-19 RT-MCDA-BS assay in clinical samples {#s3f}
-----------------------------------------------------------

A total of 65 RNA samples from the acute phase and convalescent patients, which were initially detected using rRT-qPCR in Guizhou province CDC in 2020, were tested to verify the feasibility of our assay. Our COVID-19 RT-MCDA-BS assay detected 22 (33.8%) positive results from different types of clinical specimens (*e.g.*, face, nasal, anal and pharyngeal swabs) while rRT-PCR only found 20 (30.7%) positive results ([Table S3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). The data suggested our COVID-19 RT-MCDA-BS assay is more powerful in detecting COVID-19 patients, especially for those with very low virus loads. Furthermore, no positive results were obtained from these samples collected from non-COVID-19 patients ([Table S4](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)).

Discussion {#s4}
==========

With the unexpected occurrence of SARS-CoV-2 infection in Wuhan, the novel human coronavirus has since spread within China and other regions/countries \[[@C14]\]. Hence, it is vital to develop adequate diagnosis techniques, which can provide a simple, rapid, reliable and easy-to-use strategy to detecting SARS-CoV-2 infection. Such diagnosis methods are required not only in countries where COVID-19 are spreading but also in countries threatened by COVID-19. To tackle the pandemic efficiently, we successfully devised a novel method for diagnosis of COVID-19, termed COVID-19 RT-MCDA-BS assay.

COVID-19 RT-MCDA-BS assay merges reverse transcription, cDNA isothermal amplification, multiplex detection with nano-biosensor achieving the rapid diagnosis of COVID-19 in a one-step and single-tube reaction. An extremely simple instrument, such as a heating block, a water bath or even a thermos cup which can maintain a fixed temperature (64°C) for 30 min, is sufficient for COVID-19 RT-MCDA-BS test. Importantly, the biosensor provides an easy-to-use platform, which could objectively and visually indicate the COVID-19 RT-MCDA results, and eliminate the use of special colorimetric indicator such as electrophoresis and optical equipment. The whole diagnosis process of COVID-19 RT-MCDA-BS assay- including clinical sample collection (3 min), rapid template preparation (15 min), isothermal amplification (35 min) and result reporting (within 2 min)-can be completed within 1 h. Herein, COVID-19 RT-MCDA-BS is a economical, rapid and technically simple method, which provides a measurement of practicality for \'on-site\', field and clinical settings, especially for economically impoverished regions.

F1ab-MCDA and N-MCDA primer sets were designed targeting ten regions of F1ab and N gene, respectively, ensuring the high selectivity for COVID-19 diagnosis. The specificity analysis demonstrated that COVID-19 RT-MCDA-BS could correctly diagnose the target pathogens with no false positive results observed from non-SARS-CoV-2 templates, including bacterial, fungi and viral genomic templates ([Table S2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). Furthermore, COVID-19 RT-MCDA-BS assay could simultaneously detects two target genes (F1ab and N) in a on-step isothermal reaction, which ensures the reliability for COVID-19 diagnosis, eliminating the chance getting false-positive or false-negative results compared to other COVID-19 diagnosis methods that only detects a molecular marker (*e.g.*, F1ab biomarker).

A detection limit analysis demonstrated that COVID-19 RT-MCDA-BS is sensitive for the reliable detection of target sequences. The sensitivity of COVID-19 RT-MCDA-BS is very high with pure plasmid template down to 5 copies (each of F1ab-plasimd or N-plasmid) per reaction, which was completely accordance with the detection results obtained from F1ab-RT-MCDA-BS and N-RT-MCDA-BS assays ([fig. 4](#F4){ref-type="fig"}, [S4 and S5](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). Compared to the singlex F1ab-RT-MCDA-BS and N-RT-MCDA-BS assays, COVID-19 RT-MCDA-BS did not show decreased or improved analytical sensitivity.

A total 65 RNA samples isolated form face, nasal, anal and pharyngeal swabs of the COVID-19 patients were examined to demonstrate the assay\'s feasibility in clinic. The data suggested that COVID-19 RT-MCDA-BS assay was able to analyse different types of clinical samples ([Table S3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). There were 22 RNA samples tested positive by COVID-19 RT-MCDA-BS assay, whereas only 20 RNA samples shown positive by rRT-PCR in Guizhou province CDC. The findings suggested our COVID-19 RT-MCDA-BS assay is more powerful in detecting COVID-19 patients, especially for those with very low virus loads ([Table S3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02060-2020.figures-only#fig-data-supplementary-materials)). The lower diagnosis rate of rRT-PCR might be reasoned by the presence of inhibitors which specifically affect to the rRT-PCR assay or the low copy numbers of the SARS-CoV-2 RNA templates which is out of rRT-PCR assay\'s detection limit. Moreover, isothermal amplification-based assays, including MCDA-based methods (*e.g.*, RT-MCDA-BS test), was less sensitive to various inhibitors, or was less affected by the presence of various salts from sample buffer, or could tolerate the inhibitory effect of the large amounts of nucleic acids \[[@C15]\]. Particularly, no positive results were obtained from non-COVID-19 samples, which further validated the analytical specificity of COVID-19 RT-MCDA-BS assay.

Conclusion {#s5}
==========

We devised a method (COVID-19 RT-MCDA-BS) to diagnose COVID-19 using reverse transcription, multiplex detection and isothermal amplification coupled with a nanoparticles-based biosensor. Our data demonstrated that COVID-19 RT-MCDA-BS was a highly specific and sensitive diagnostic assay, and could be used as an attractive laboratory tool for diagnosis of COVID-19 in different types of clinical specimens. The diagnosis test of COVID-19 RT-MCDA-BS could be finished within 1h, and did not rely on expensive reagents and apparatus. Collectively, its rapidity, low cost and ease-to-use characteristics make the COVID-19 RT-MCDA-BS method an ideal tool for use in field, primary and clinical laboratories, especially for resource-poor settings.
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